# Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma.

> **NCT07664007** · NA · COMPLETED · sponsor: **Instituto de Investigación Sanitaria Aragón** · enrollment: 18 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DIETARY_SUPPLEMENT:** Eicosapentaenoic acid oral lipidic emulsion
- **DIETARY_SUPPLEMENT:** Pacebo oral lipidic emulsion

## Key facts

- **NCT ID:** NCT07664007
- **Lead sponsor:** Instituto de Investigación Sanitaria Aragón
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-04
- **Primary completion:** 2023-09-17
- **Final completion:** 2025-06-20
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-06-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07664007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07664007, "Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07664007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*